INCIDENCE OF RHEUMATOID ARTHRITIS IN PATIENTS WITH NEW ONSET OF MUSCULOSKELETAL SYMPTOMS AND ANTI-CCP POSITIVITY COMPARED TO ANTI-CCP NEGATIVE PATIENTS

S. Dauth1,2; M. Köhm1,2,3; T. Oberwahrenbrock1,2, U. Henkemeier2,4.

Background: Rheumatoid Arthritis (RA) is a chronic inflammatory joint disease. Symptom forms for its early detection and diagnosis are of high importance: prompt treatment improves clinical and structural outcome. Autoantibodies against cyclic citrullinated proteins (anti-CCP) have been associated with RA-development. Non-specific musculoskeletal (nsMSK) symptoms are often described prior to RA development. Majority of patients with nsMSK symptoms present to their general practice (GP) first. Studies of early arthritis cohorts have shown that many early arthritis patients cannot be accurately diagnosed at their first visit and are often referred as undifferentiated arthritis patients.

Methods: To evaluate the incidence of anti-CCP positivity in patients with new onset of nsMSK symptoms and the incidence of RA in these patients over a 3-year follow-up period compared to anti-CCP negative patients.

Results: From 978 included patients, 105 (10.7%) were CCPoint® positive. 96 were tested with ELISA and 27 (28.1%) were confirmed anti-CCP positive. 9 (33.3%) were diagnosed with RA at the first RD visit (study visit 2); 4 further patients were diagnosed with RA during the follow-up (FU) period so far. Overall, 48.1% of ELISA-positive (ELISA+) patients were diagnosed with RA up to now; 11 ELISA+ patients are still in the FU period of the study. Of the 868 CCPoint® negative patients, currently, 282 have filled out a 1-year FU questionnaire; 3.5% of those reported a RA diagnosis (Table 1). As expected, clinical parameters at V2 (e.g. CRP, swollen and tender joint count) were worse in the ELISA+/RA+ group compared to the ELISA-/RA- group, as expected.

Conclusion: Currently, 48.1% of anti-CCP+ (ELISA) patients have received a RA diagnosis, whereas 3.5% of the anti-CCP- (CCPoint®) received a RA diagnosis (patient reported), which underlines, that anti-CCP can be used as a marker to identify patients in GP setting. While clinical parameters are correlated with the diagnosis of RA, they are not suited for predicting future RA development alone. Anti-CCP possibly in combination with additional parameters imaging, might increase the likelihood to early diagnose or predict RA development.

Table 1. Number and percentage of patients with a RA diagnosis

<table>
<thead>
<tr>
<th>Anti-CCP status</th>
<th>Visit 2</th>
<th>Follow-up*</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Point-of-Care Test -</td>
<td>-</td>
<td>3.5% (10 of 282)</td>
<td>3.5% (10 of 282)*</td>
</tr>
<tr>
<td>Point-of-Care Test + / ELISA -</td>
<td>2.9% (2 of 69)</td>
<td>0% (0 of 34)</td>
<td>2.9% (2 of 69)</td>
</tr>
<tr>
<td>Point-of-Care Test + / ELISA +</td>
<td>33.3% (9 of 27)</td>
<td>14.8% (4 of 27)</td>
<td>48.1% (13 of 27)*</td>
</tr>
</tbody>
</table>

* 1 year-questionnaire for Point-of-Care Test and ELISA negative patients or every 6 months for a total follow-up of 36 months or until RA-diagnosis.

Disclosure of Interests: Stephanie Dauth Grant/research support from: BMS, Michala Köhm Grant/research support from: Pfizer, Janssen, BMS, Leo, Consultant of: BMS, Pfizer, Speakers bureau: Pfizer, BMS, Janssen, Novartis, Timm Oberwahrenbrock Grant/research support from: BMS, Ulf Henkemeier: None declared, Tanja Rossmanith Grant/research support from: Janssen, BMS, Leo, Pfizer, Karola Mengenthal Grant/research support from: BMS, Julia J. Petersen Grant/research support from: Pfizer, Harald Burkhardt Grant/ research support from: Pfizer, Roche, Abbvie, Consultant of: Sanofi, Pfizer, Roche, Abbvie, Boehringer Ingelheim, UCB, Eli Lilly, Chugai, Bristol Myer Scrivens, Janssen, and Novartis, Speakers bureau: Sanofi, Pfizer, Roche, Abbvie, Boehringer Ingelheim, UCB, Eli Lilly, Chugai, Bristol Myer Scrivens, Janssen, and Novartis, Frank Behrens Grant/research support from: Pfizer, Janssen, Chugai, Celgene, Lilly and Roche, Consultant of: Abbott, Abbvie, Lilly, Novartis, Genzyme, Boehringer, Janssen, MSD, Celgene, Roche and Chugai.

DOI: 10.1136/annrheumdis-2020-eular.5463

SAT0033

INTO PATHOGENESIS OF EARLY RHEUMATOID ARTHRITIS ENDOTYPES

C. Duncan1, E. Hunter2, C. Koutsothanasis3, M. Sailer4, A. Akouilitch5, I. McInnes1, C. Goodyear1. 1University of Glasgow, Glasgow, United Kingdom; 2Oxford Biodynamics, Oxford, United Kingdom

Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease with substantial immunopathogenic heterogeneity. It is well established that early diagnosis and initiation of effective therapy is crucial to prevent loss of function. Previously, various RA treatment trajectories have been identified, however there are currently no clinically validated biomarkers that can identify these trajectories at the start of treatment. Evaluation of the structural genome has revealed that chromosome conformation signatures (CCS) offer great potential as binary, informative biomarkers, and have been previously shown to predict early RA patient response to Methotrexate with 90% sensitivity (1). These signatures can also reveal highly regulated areas of the genome, which may be underpinning disease endotypes.

Objectives: The objective of this study was to evaluate the structural genome in early RA over longitudinal samples to determine whether it is associated with treatment trajectories.

Methods: Patient data and samples were from the Scottish Early Rheumatoid Arthritis (SERA) cohort; a pan-Scotland inception cohort. CDAI, DAS28 ESR and DAS28 CRP measurements were calculated at baseline, 6 months and 12 months to determine longitudinal treatment response. From 3 principal longitudinal response trajectories, 18 patients (who had equivalent disease activity at baseline) were chosen to investigate the structural genome. These 18 comprised of responders (R), non-responders (NR) and initial responders (IR; low disease activity/remission at 6 months but moderate/high disease activity at 12 months) with 6 patients per group at each time point. 20 pooled healthy samples were used as a comparator population. Episwitch libraries were probed on 180k Agilent SureSelect custom arrays that were designed using Episwitch propriety information and publicly available data from Walsh et al. Microarray data was analysed using the Limma package within R studio.

Results: Episwitch array analysis showed that there were >10,000 statistically significant differential chromosomal loops between R, NR and IR. Evaluation of the 3 trajectory groups (R, NR and IR) taking into account the healthy chromosomal conformation, revealed an RA-associated structural epigenome that comprised of 10,445 chromosomal loops that were stable, over the three time points. Subsequent analysis of the distinct treatment
trajectories demonstrated that 3683 of the stable, disease-associated chromosomal loops were shared by all 3. However, 4496 were associated with distinct response trajectories, with 1221, 2574 and 701 loops unique to R, NR and IR respectively.

**Conclusion:** The stable chromosomal architecture unique to each treatment trajectory suggests that various underlying molecular endotypes may exist. Moreover, the stable loops common to all groups allude to a baseline level of dysregulation in RA and offers the potential to discover novel drivers of disease. This work provides the foundation to further our understanding of RA pathogenesis and the potential of finding a biomarker that would be of significant value in a clinical setting.

**References:**

**Disclosure of Interests:** Caitlin Duncan: None declared, Ewan Hunter: None declared, Christina Koutsothanasi: None declared, Matthew Saltier: None declared, Alexandre Aukulitch: None declared, Iain McInnes Grant/research support from: Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Janssen, and UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Gilead, Janssen, Novartis, Pfizer, and UCB, Carl Goodyear: None declared.

**DOI:** 10.1136/annrheumdis-2020-eular.5714

**SAT0034**

**CLINICAL SIGNIFICANCE OF ANTI-CARBAMYLATED PROTEIN ANTIBODIES IN PREMENOPAUSAL RHEUMATOID ARTHRITIS WOMEN: RELATION TO DISEASE ACTIVITY AND BONE LOSS**

**R. Eleneir**1, R. Bastawy2, R. Ghazala3, M. Abdelrazek4, N. Elsaywy5

1. Faculty of Medicine, Alexandria University, Physical Medicine, Rheumatology and Rehabilitation, Alexandria, Egypt; 2. Alexandria University, Alexandria, Egypt; 3. Alexandria University, Medical Biochemistry, Alexandria, Egypt; 4. Alexandria University, Alexandria, Egypt; 5. Alexandria University, Alexandria, Egypt

**Background:** Anti carbamylated protein anti carP are present in patients with Rheumatoid Arthritis RA and are associated with erosions. However their association with systemic or local bone loss in RA patients is still not confirmed.

**Objectives:** The purpose of this study was to measure the serum level of anti carP in premenopausal women with RA and determine its relation to disease activity and bone loss.

**Methods:** This case control study was conducted on forty eight RA premenopausal female patients diagnosed according to 2010 ACR/EULAR criteria and forty eight ages and body mass index matched healthy premenopausal females. RA patients with other autoimmune diseases, viral hepatitis malignancy or erosive joint disease and systemic diseases that affect bone quality were excluded from the study. All RA women were subjected to history taking, clinical examination, assessment of disease activity using disease activity score-28 DAS28 and clinical disease activity index CDAI functional assessment using health assessment questionnaire HAQ physical activity assessment using international physical activity questionnaire short form IPAQ fatigue assessment using modified fatigue impact scale MFIS, routine laboratory investigations, serological tests as well as Anti carP using ELISA kit. Moreover the bone mineral density was measured by a lunar Prodigy Advanced DEXA scanner system and plain x-ray of both hands and wrists in the anteroposterior view was done to assess the juxta articular osteopenia and erosions.

**Results:** Anti carP level was significantly higher in RA patients than in healthy controls table 1. The serum level of anti carP had a significant positive correlation with RA DAS, CDAI, HAQ, IPAQ, MFIS and erosion and joint space narrowing in original sharp score. Also the anti carP had a significant negative correlation with the bone mineral density BMD of spine. The AUC of anti carP level showed a high level of accuracy AUC 0.857 figure 1 and the calculated cutoff value >65 can precisely discriminate subjects with RA from those without RA with 85.42% sensitivity and 85.11% specificity.

**Conclusion:** Anti carbamylated antibodies were higher in premenopausal RA compared to ages and body mass index matched healthy women. Anti carP are associated with higher RA disease activity, increased disability and decreased physical activity. Moreover anti carP are associated with systemic trabecular bone loss manifested by decreased bone mineral density of the spine as well as local bone loss as manifested by increased number of joint erosions in premenopausal RA women.

**References:**

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2020-eular.637

**SAT0035**

**RESPONSE TO ABATACEPT OF DIFFERENT PATTERNS OF INTERSTITIAL LUNG DISEASE IN RHEUMATOID ARTHRITIS: NATIONAL MULTICENTER STUDY OF 263 PATIENTS**


**Table 1. Comparison between the patient and healthy groups according to anti carP level**

<table>
<thead>
<tr>
<th>Anti-carP</th>
<th>RA patients</th>
<th>Healthy control</th>
<th>U</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Min – Max</td>
<td>15.0 – 90.0</td>
<td>1.0 – 78.50</td>
<td>322.0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>71.24 ± 14.70</td>
<td>45.99 ± 21.99</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>72.75 (70.5–78.3)</td>
<td>55.0 (32.5–61.5)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Figure 1. ROC curve for anti-carP to diagnose RA patients from healthy subjects**